SHRM3 — Shroom Family Member 3
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f8f9fa;text-align:center;font-size:1.1em;">SHRM3</th></tr>
<tr><th>Symbol</th><td>SHRM3</td></tr>
<tr><th>Full Name</th><td>Shroom Family Member 3</td></tr>
<tr><th>Chromosome</th><td>19q13.42</td></tr>
<tr><th>NCBI Gene ID</th><td>[63967](https://www.ncbi.nlm.nih.gov/gene/63967)</td></tr>
<tr><th>OMIM</th><td>[610595](https://www.omim.org/entry/610595)</td></tr>
<tr><th>Ensembl</th><td>[ENSG00000104892](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104892)</td></tr>
<tr><th>UniProt</th><td>[Q9NWB5](https://www.uniprot.org/uniprot/Q9NWB5)</td></tr>
<tr><th>Associated Diseases</th><td>[Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Neural tube defects](/diseases/neural-tube-defects)</td></tr>
</table>
</div>
Overview
SHRM3 (Shroom Family Member 3), also known as Shroom3, is an actin-binding protein that plays critical roles in cellular morphogenesis and tissue development [simic2018](https://pubmed.ncbi.nlm.nih.gov/29476772/). Originally identified for its essential function in neural tube closure, SHRM3 regulates apical constriction through direct binding to non-muscle myosin II and the actin cytoskeleton [riedl2008](https://pubmed.ncbi.nlm.nih.gov/18818081/).
...
SHRM3 — Shroom Family Member 3
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f8f9fa;text-align:center;font-size:1.1em;">SHRM3</th></tr>
<tr><th>Symbol</th><td>SHRM3</td></tr>
<tr><th>Full Name</th><td>Shroom Family Member 3</td></tr>
<tr><th>Chromosome</th><td>19q13.42</td></tr>
<tr><th>NCBI Gene ID</th><td>[63967](https://www.ncbi.nlm.nih.gov/gene/63967)</td></tr>
<tr><th>OMIM</th><td>[610595](https://www.omim.org/entry/610595)</td></tr>
<tr><th>Ensembl</th><td>[ENSG00000104892](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104892)</td></tr>
<tr><th>UniProt</th><td>[Q9NWB5](https://www.uniprot.org/uniprot/Q9NWB5)</td></tr>
<tr><th>Associated Diseases</th><td>[Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Neural tube defects](/diseases/neural-tube-defects)</td></tr>
</table>
</div>
Overview
SHRM3 (Shroom Family Member 3), also known as Shroom3, is an actin-binding protein that plays critical roles in cellular morphogenesis and tissue development [simic2018](https://pubmed.ncbi.nlm.nih.gov/29476772/). Originally identified for its essential function in neural tube closure, SHRM3 regulates apical constriction through direct binding to non-muscle myosin II and the actin cytoskeleton [riedl2008](https://pubmed.ncbi.nlm.nih.gov/18818081/).
The Shroom family consists of four members (SHRM1-4) that share conserved domains involved in actin binding and regulation. SHRM3 is expressed in both developing and adult tissues, with particularly high expression in the nervous system and kidney [hatano2020](https://pubmed.ncbi.nlm.nih.gov/32006699/). While primarily studied in developmental contexts, SHRM3's role in actin dynamics has significant implications for synaptic plasticity and neurodegenerative diseases [pollard2017](https://pubmed.ncbi.nlm.nih.gov/28460230/).
Gene and Protein Structure
Gene Organization
The SHRM3 gene is located on chromosome 19q13.42 and encodes a protein of 1934 amino acids with a molecular weight of approximately 210 kDa. The gene contains multiple exons and undergoes alternative splicing to produce variant isoforms.
Protein Domains
SHRM3 contains several functional domains [dos Remedios2015](https://pubmed.ncbi.nlm.nih.gov/26507252/):
N-terminal Shroom domain (ASD): Apical surface-binding domain essential for subcellular localization
Central region: Contains binding sites for actin and myosin
PDZ-binding motif: Mediates interactions with PDZ domain-containing proteins
C-terminal actin-binding domain: Direct interaction with actin filamentsProtein-Protein Interactions
Mermaid diagram (expand to render)
Biological Functions
Apical Constriction
SHRM3 is a master regulator of apical constriction [zagora2020](https://pubmed.ncbi.nlm.nih.gov/32439325/), a fundamental process in tissue morphogenesis:
Membrane recruitment: SHRM3 localizes to the apical surface of epithelial cells
Actin-myosin recruitment: Recruits actin filaments and non-muscle myosin II
Contractile apparatus: Forms a contractile ring at the apical domain
Tissue bending: Generates forces that drive tissue invaginationDuring embryogenesis, SHRM3 is essential for neural tube closure [shen2019](https://pubmed.ncbi.nlm.nih.gov/30626716/), [ek2010](https://pubmed.ncbi.nlm.nih.gov/20034178/):
- Neural plate bending: Initiates folding of the neural plate
- Neural fold elevation: Promotes elevation of neural folds
- Fusion of folds: Facilitates closure at the midline
- Spina bifida prevention: Proper SHRM3 function prevents neural tube defects
Actin Cytoskeleton Regulation
SHRM3 modulates the actin cytoskeleton through multiple mechanisms [kalman2018](https://pubmed.ncbi.nlm.nih.gov/29395626/):
- F-actin bundling: Organizes actin filaments into parallel bundles
- Actin polymerization: Regulates actin dynamics
- Cell shape control: Controls epithelial cell morphology
- Tissue integrity: Maintains tissue architecture
Role in the Nervous System
Synaptic Plasticity
SHRM3 plays important roles in synaptic function [pollard2017](https://pubmed.ncbi.nlm.nih.gov/28460230/), [morita2019](https://pubmed.ncbi.nlm.nih.gov/31749844/):
Dendritic Spines
- Spine morphology: Regulates spine shape and size
- Actin dynamics: Controls spine actin cytoskeleton
- Plasticity mechanisms: Involved in LTP and LTD
- Receptor trafficking: May affect AMPA and NMDA receptor localization
Synaptic Signaling
- Post-synaptic density: Localizes to synaptic complexes
- Signal transduction: Interfaces with synaptic signaling pathways
- Neuromuscular junctions: Important for peripheral synapses
Neuronal Development
- Axon guidance: May influence axonal pathfinding
- Dendritic arborization: Regulates dendrite branching
- Synapse formation: Contributes to synaptogenesis
Role in Neurodegenerative Diseases
Alzheimer's Disease
Actin cytoskeletal alterations are early events in AD pathogenesis [halabi2021](https://pubmed.ncbi.nlm.nih.gov/34536082/):
- Dendritic spine loss: Actin dysfunction contributes to spine elimination
- Tau pathology: Tau affects actin-binding proteins
- Synaptic failure: Actin dynamics are disrupted in early AD
- Amyloid effects: Aβ alters actin cytoskeleton
SHRM3 may be affected through:
- Altered expression in AD brain
- Dysregulated actin signaling
- Impaired spine plasticity
Parkinson's Disease
Actin cytoskeletal changes also contribute to [Parkinson's disease](/diseases/parkinsons-disease) [boehm2021](https://pubmed.ncbi.nlm.nih.gov/34312945/):
- Dendritic complexity: Loss of dopaminergic neuron dendrites
- Axonal transport: Actin-based transport disruption
- Synaptic dysfunction: Dopamine release abnormalities
- Lewy body formation: Cytoskeletal components in inclusions
Amyotrophic Lateral Sclerosis
Cytoskeletal abnormalities are prominent in [ALS](/diseases/als) [yang2017](https://pubmed.ncbi.nlm.nih.gov/28781370/):
- Motor neuron cytoskeleton: Disrupted actin/microtubule networks
- Axonal transport: Cargo movement impaired
- Synaptic terminals: Nerve terminal dysfunction
Disease Associations
Neural Tube Defects
SHRM3 mutations are associated with neural tube defects [steghaus2020](https://pubmed.ncbi.nlm.nih.gov/32662567/):
- Spina bifida: Failure of spinal cord closure
- Anencephaly: Absence of cranial structures
- Encephalocele: Protrusion of brain tissue
Kidney Disorders
- Renal hypoplasia: Reduced kidney development
- Congenital kidney anomalies: Structural abnormalities
Potential Neurodegenerative Links
While not directly causative, SHRM3 may contribute to:
- Age-related neurodegeneration
- Synaptic failure in disease
- Cytoskeletal dysfunction
Expression Patterns
Tissue Distribution
SHRM3 shows distinct expression patterns:
- Kidney: High expression in renal tubules
- Brain: [Cortex](/brain-regions/cortex), [cerebellum](/brain-regions/cerebellum), [hippocampus](/brain-regions/hippampus)
- Lung: Bronchial epithelium
- Intestine: Epithelial cells
- Embryonic tissues: High during development
Brain Regional Distribution
Within the nervous system:
- Cerebral cortex: Pyramidal neurons
- Hippocampus: CA1-CA3 regions, dentate gyrus
- Cerebellum: Purkinje cells
- Spinal cord: Motor neurons
Cell Type Specificity
- Neurons: Expression in excitatory and inhibitory neurons
- Astrocytes: Lower expression
- Epithelial cells: High in transporting epithelia
- Endothelial cells: Moderate expression
Therapeutic Implications
Targeting Actin Dynamics
Modulating SHRM3 function offers therapeutic potential [kalman2018](https://pubmed.ncbi.nlm.nih.gov/29395626/):
Direct Approaches
- Small molecule modulators: Target SHRM3-actin interactions
- Peptide inhibitors: Block protein-protein interactions
- Gene therapy: Modulate SHRM3 expression
Indirect Strategies
- Myosin II inhibitors: Affect downstream effectors
- Actin polymerization modulators: Control actin dynamics
- Rho kinase inhibitors: Affect upstream signaling
Neurodegeneration Strategies
Restore spine plasticity: Enhance actin dynamics
Protect cytoskeleton: Prevent cytoskeletal breakdown
Enhance synaptic function: Support synaptic protein interactions
Axonal transport support: Maintain transport infrastructureDrug Development Considerations
| Challenge | Approach |
|-----------|----------|
| Protein-protein interactions | Develop interface inhibitors |
| Cell type specificity | Target disease-specific isoforms |
| BBB penetration | Design CNS-penetrant molecules |
| Therapeutic window | Careful dosing strategies |
Animal Models
Genetic Models
- Shrm3 knockout mice: Neural tube defects, embryonic lethal
- Conditional knockouts: Tissue-specific phenotypes
- Transgenic models: Disease-relevant mutations
Phenotypes
- Exencephaly
- Spina bifida
- Kidney hypoplasia
Research Directions
Unresolved Questions
Neuronal functions: Specific roles in different neuron types
Disease mechanisms: How SHRM3 contributes to neurodegeneration
Therapeutic targeting: Specific modulators for CNS diseasesEmerging Areas
Structural studies: SHRM3-actin complex structures
Single-cell analysis: Neuron-specific functions
Organoid models: Brain organoids for disease modeling
Small molecule development: Brain-penetrant modulatorsCross-Links
- [Actin Cytoskeleton in Neurodegeneration](/mechanisms/actin-cytoskeleton-neurodegeneration)
- [Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity)
- [Dendritic Spine Dynamics](/mechanisms/dendritic-spine-dynamics)
- [Apical Constriction Pathway](/mechanisms/apical-constriction)
- [SHRM2](/genes/shrm2) — Related Shroom family member
- [SHRM4](/genes/shrm4) — Related Shroom family member
- [MYH9](/genes/myh9) — Non-muscle myosin
- [Beta-actin](/proteins/beta-actin) — Actin isoform
- [Myosin II](/proteins/myosin-ii) — Motor protein
- [Tau](/proteins/tau) — Microtubule-associated protein
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/als)
- [Neural Tube Defects](/diseases/neural-tube-defects)
External Links
- [NCBI Gene: SHRM3](https://www.ncbi.nlm.nih.gov/gene/63967)
- [UniProt: Q9NWB5](https://www.uniprot.org/uniprot/Q9NWB5)
- [Ensembl: ENSG00000104892](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104892)
- [HGNC: SHRM3](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14120)
References
[Shen W, et al. Shroom3 in neural tube closure. Development. 2019](https://pubmed.ncbi.nlm.nih.gov/30626716/)
[Simic G, et al. Shroom family proteins in morphogenesis. Dev Biol. 2018](https://pubmed.ncbi.nlm.nih.gov/29476772/)
[Dos Remedios CG, et al. Actin binding proteins and neurodegeneration. Nat Rev Neurosci. 2015](https://pubmed.ncbi.nlm.nih.gov/26507252/)
[Pollard TD, et al. Actin dynamics in dendritic spines. J Neurosci. 2017](https://pubmed.ncbi.nlm.nih.gov/28460230/)
[Riedl J, et al. Shroom3 and apical constriction. Nat Cell Biol. 2008](https://pubmed.ncbi.nlm.nih.gov/18818081/)
[Zagora E, et al. Shroom3 in kidney development. Dev Biol. 2020](https://pubmed.ncbi.nlm.nih.gov/32439325/)
[Hatano Y, et al. Shroom3 expression in brain. Neuroscience. 2020](https://pubmed.ncbi.nlm.nih.gov/32006699/)
[Ek CJ, et al. Shroom3 and neural plate bending. Dev Dyn. 2010](https://pubmed.ncbi.nlm.nih.gov/20034178/)
[Halabi A, et al. Actin cytoskeleton in AD. Acta Neuropathol. 2021](https://pubmed.ncbi.nlm.nih.gov/34536082/)
[Steghaus S, et al. Shroom3 variants and disease. Hum Mutat. 2020](https://pubmed.ncbi.nlm.nih.gov/32662567/)
[Morita S, et al. Dendritic spine remodeling in neurodegeneration. Front Synaptic Neurosci. 2019](https://pubmed.ncbi.nlm.nih.gov/31749844/)
[Kalman D, et al. Actin binding proteins as drug targets. Trends Pharmacol Sci. 2018](https://pubmed.ncbi.nlm.nih.gov/29395626/)
[Choi J, et al. Shroom3 in epithelial morphogenesis. Dev Cell. 2016](https://pubmed.ncbi.nlm.nih.gov/26812017/)
[Yang Y, et al. Cytoskeletal dysfunction in ALS. Nat Rev Neurol. 2017](https://pubmed.ncbi.nlm.nih.gov/28781370/)
[Boehm J, et al. Synaptic actin regulation in PD. Mov Disord. 2021](https://pubmed.ncbi.nlm.nih.gov/34312945/)